TrialJournal of pharmacokinetics and pharmacodynamics2014

Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis.

Chuanpu Hu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.